BCPCHIGH SIGNALFINANCIAL10-K

BCPC delivered exceptional financial performance with gross profit surging 288% and net income increasing 284%, while dramatically increasing share buybacks from $5.7M to $107.6M.

This represents a fundamental improvement in BCPC's profitability and cash generation capability, suggesting either significant operational improvements, beneficial pricing dynamics, or potentially one-time gains that warrant investigation. The massive increase in share buybacks signals management's strong confidence in the business and commitment to returning excess cash to shareholders.

Comparing 2026-02-20 vs 2025-02-21View on EDGAR →
FINANCIAL ANALYSIS

BCPC demonstrated remarkable financial transformation with gross profit nearly quadrupling to $370.6M and net income tripling to $154.8M, far outpacing the modest 13.6% revenue growth to $799M, indicating substantial margin expansion. Operating cash flow grew a solid 19% to $216.6M while the company aggressively returned capital through a 1,794% increase in share buybacks to $107.6M, and strengthened its balance sheet with 50.6% cash growth. The dramatic profitability improvement combined with strong cash generation and aggressive capital returns suggests BCPC has achieved significant operational leverage and pricing power in its specialty chemicals business.

FINANCIAL STATEMENT CHANGES
Share Buybacks
Cash Flow
+1794.3%
$5.7M$107.6M

Share repurchases increased 1794.3% — management returning capital, signals confidence in intrinsic value.

Gross Profit
P&L
+288.3%
$95.5M$370.6M

Gross profit expanding — improving pricing power or product mix shift toward higher-margin offerings.

Net Income
P&L
+284.3%
$40.3M$154.8M

Net income grew 284.3% — bottom-line growth signals improving overall business health.

Cash & Equivalents
Balance Sheet
+50.6%
$49.5M$74.6M

Cash position surged 50.6% — strong cash generation or capital raise providing significant financial cushion.

Capital Expenditure
Cash Flow
+35.8%
$36.1M$49.1M

Capital expenditure jumped 35.8% — major investment cycle underway; assess returns on deployment.

Accounts Receivable
Balance Sheet
+20%
$119.7M$143.6M

Receivables grew 20% — monitor days sales outstanding for collection efficiency.

Operating Cash Flow
Cash Flow
+19%
$182.0M$216.6M

Operating cash flow grew 19% — strong conversion of earnings to cash, healthy business fundamentals.

Current Assets
Balance Sheet
+16.5%
$313.8M$365.6M

Current assets grew 16.5% — improving short-term liquidity or inventory/receivables build.

Operating Income
P&L
+14.4%
$182.9M$209.3M

Operating income improving — cost discipline or growing revenue base absorbing fixed costs.

Revenue
P&L
+13.6%
$703.6M$799.0M

Revenue growing 13.6% — solid top-line momentum, watch margins for quality of growth.

LANGUAGE CHANGES
NEW — 2026-02-20
PRIOR — 2025-02-21
ADDED
Management's Discussion and Analysis of Financial Condition and Results of Operations 20 Item 7A.
We develop, manufacture, distribute and market specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, plant nutrition, sterilization, fumigation, and industrial markets.
Sales of value-added encapsulated products are highly dependent on overall industry economics as well as the Company's ability to leverage the results of university and field research on the animal health and production benefits of our products.
Raw Materials The raw materials utilized by us in the manufacture of our products are sourced from suppliers both domestically and internationally.
We experienced inflationary patterns in 2025, including from certain tariffs, in several categories that we source.
+7 more — sign up free →
REMOVED
Management's Discussion and Analysis of Financial Condition and Results of Operations 22 Item 7A.
We develop, manufacture, distribute and market specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition and industrial markets.
Specialty Products The Company re-packages and distributes a number of performance gases and chemicals for various uses by its customers, notably ethylene oxide, propylene oxide, and ammonia.
Significant Acquisitions On August 30, 2022, the Company's wholly-owned subsidiary Albion Laboratories, Inc.
("Albion") entered into a Stock Purchase Agreement, and closed on such transaction with Cardinal Associates Inc.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →